HAISCO PHARMACEUTICAL GROUP CO LTD
PharmaHAISCO PHARMACEUTICAL GROUP CO LTD is a pharmaceutical company focused on Respiratory, Metabolic, Immunology.
HAISCO PHARMACEUTICAL GROUP CO LTD at a Glance
- Growing R&D activity with 46 trials in last 2 years
- Leading 6 drug targets across portfolio
HAISCO PHARMACEUTICAL GROUP CO LTD's Key Drugs
HAISCO PHARMACEUTICAL GROUP CO LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
HAISCO PHARMACEUTICAL GROUP CO LTD's Recent FDA Approvals
New NDA/BLA approvals for HAISCO PHARMACEUTICAL GROUP CO LTD over the last two years — novel drugs only, excluding generics and label supplements.
HAISCO PHARMACEUTICAL GROUP CO LTD's Therapeutic Areas
HAISCO PHARMACEUTICAL GROUP CO LTD's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HAISCO PHARMACEUTICAL GROUP CO LTD's Top Competitors
HAISCO PHARMACEUTICAL GROUP CO LTD's closest competitors by therapeutic-area and drug-target overlap include GSK, Merck, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HAISCO PHARMACEUTICAL GROUP CO LTD Pipeline Snapshot
HAISCO PHARMACEUTICAL GROUP CO LTD has 32 active clinical programs from ClinicalTrials.gov — 9 Phase 3, 15 Phase 2 and 8 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 13/20 completed
- • Speed: 7 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2026-05-29
- Latest
- 2026-05-29
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges